WallStSmart

Curanex Pharmaceuticals Inc Common Stock (CURX)vsRegeneron Pharmaceuticals Inc (REGN)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

REGN leads profitability with a 28.5% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 80/100 (B+).

CURX

Avoid

23

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 8.5
Piotroski: 3/9Altman Z: 18.01

REGN

Strong Buy

80

out of 100

Grade: B+

Growth: 8.7Profit: 8.0Value: 7.3Quality: 8.5
Piotroski: 2/9Altman Z: 4.44
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CURX.

REGNUndervalued (+36.9%)

Margin of Safety

+36.9%

Fair Value

$1497.56

Current Price

$920.69

$576.87 discount

UndervaluedFair: $1497.56Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CURX3 strengths · Avg: 9.7/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
18.0110/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

REGN6 strengths · Avg: 9.7/10
Operating MarginProfitability
30.4%10/10

Strong operational efficiency at 30.4%

Revenue GrowthGrowth
36.3%10/10

Revenue surging 36.3% year-over-year

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4410/10

Safe zone — low bankruptcy risk

Market CapQuality
$98.40B9/10

Large-cap with strong market position

Profit MarginProfitability
28.5%9/10

Keeps 29 of every $100 in revenue as profit

Areas to Watch

CURX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.53M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

REGN1 concerns · Avg: 3.0/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CURX

The strongest argument for CURX centers on Price/Book, Altman Z-Score, Debt/Equity.

Bull Case : REGN

The strongest argument for REGN centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 28.5% and operating margin at 30.4%. Revenue growth of 36.3% demonstrates continued momentum.

Bear Case : CURX

The primary concerns for CURX are Revenue Growth, EPS Growth, Market Cap.

Bear Case : REGN

The primary concerns for REGN are Piotroski F-Score.

Key Dynamics to Monitor

CURX profiles as a value stock while REGN is a growth play — different risk/reward profiles.

REGN is growing revenue faster at 36.3% — sustainability is the question.

REGN generates stronger free cash flow (1.5B), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

REGN scores higher overall (80/100 vs 23/100), backed by strong 28.5% margins and 36.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Curanex Pharmaceuticals Inc Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. The company is headquartered in Jericho, New York.

Regeneron Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.

Want to dig deeper into these stocks?